Provided by Tiger Trade Technology Pte. Ltd.

Eton Pharmaceuticals, Inc.

22.97
-0.8400-3.53%
Post-market: 21.72-1.2475-5.43%19:50 EDT
Volume:583.42K
Turnover:13.58M
Market Cap:626.72M
PE:-134.34
High:23.96
Open:23.90
Low:22.85
Close:23.81
52wk High:23.96
52wk Low:11.09
Shares:27.28M
Float Shares:17.82M
Volume Ratio:0.97
T/O Rate:3.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1710
EPS(LYR):-0.1710
ROE:-18.19%
ROA:3.59%
PB:23.96
PE(LYR):-134.34

Loading ...

Eton Pharmaceuticals Inc - to Pay $14 Mln Upfront and 8% Royalty - SEC Filing

THOMSON REUTERS
·
Mar 02

Eton Pharmaceuticals : Entered Into Licensing Agreement and Acquired U.S. Rights to Hemangeol Oral Solution From Pierre Fabre Medicament Sas

THOMSON REUTERS
·
Mar 02

Eton Pharmaceuticals Inc: Transaction Was Financed by Company's Cash on Hand

THOMSON REUTERS
·
Mar 02

Eton Pharmaceuticals Inc - Deal Expected Accretive to 2026 Earnings - SEC Filing

THOMSON REUTERS
·
Mar 02

Eton Pharmaceuticals acquires U.S. commercialization rights to Hemangeol oral solution from Pierre Fabre

Reuters
·
Mar 02

Eton Pharmaceuticals price target raised to $37 from $35 at H.C. Wainwright

TIPRANKS
·
Mar 02

Analysts Offer Insights on Healthcare Companies: Eton Pharmaceuticals (ETON) and Atai Beckley N.V. (ATAI)

TIPRANKS
·
Feb 27

Eton Pharmaceuticals Rises After an FDA Approval But Pares Gains

Dow Jones
·
Feb 26

Eton Pharmaceuticals announces FDA approval for Desmoda Oral Solution

TIPRANKS
·
Feb 26

US FDA approves Eton Pharma's hormonal disorder drug

Reuters
·
Feb 26

FDA approves Eton Pharmaceuticals’ DESMODA desmopressin oral solution

Reuters
·
Feb 26

Eton Pharmaceuticals Announces U.S. FDA Approval for Desmoda™ (Desmopressin Acetate) Oral Solution

THOMSON REUTERS
·
Feb 26

Eton Pharmaceuticals Inc - Desmoda Commercial Launch Expected on March 9TH

THOMSON REUTERS
·
Feb 26

Eton Pharmaceuticals Inc - Desmoda Expected Peak Sales of $30 Mln-$50 Mln Annually

THOMSON REUTERS
·
Feb 26

Eton Pharmaceuticals trading halted, news pending

TIPRANKS
·
Feb 26

NASDAQ TRADE HALT HALT NEWS PENDING AT 12:33 PM

Reuters
·
Feb 26

Eton Pharmaceuticals to Hold One-on-One Meetings at Leerink Partners Global Healthcare Conference

Reuters
·
Feb 20

Eton licenses U.S. marketing rights to ultra-rare disease product candidate

TIPRANKS
·
Feb 02

Eton Pharmaceuticals Plans 2026 Launch of FDA-Reviewed Ultra-Rare Disease Product, Expands Pipeline and Pursues Additional High-Value Opportunities

Reuters
·
Feb 02

Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate

THOMSON REUTERS
·
Feb 02